Cargando...
ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer
BACKGROUND: The frequency of ROS1 rearrangement in non-small cell lung cancers has been reported from 1.6% to 2.3%. MATERIALS AND METHODS: We examined 105 lung adenocarcinoma patients for ROS1 rearrangement which were negative for EGFR and anaplastic lymphoma kinase. Clinical characteristics of ROS1...
Gardado en:
| Publicado en: | Lung India |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Medknow Publications & Media Pvt Ltd
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5592750/ https://ncbi.nlm.nih.gov/pubmed/28869223 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/lungindia.lungindia_116_17 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|